ClinicalTrials.gg
CompletedNCT06776679Updated May 1, 2025

A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants

A Phase 1 interventional study of [14C]-BGB-16673 in Healthy Volunteers, sponsored by BeiGene. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to determine the absorption, metabolism, and excretion of [14C]-BGB-16673 and to characterize and determine, where possible, the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18.0 and 32.0 kg/m², inclusive.
  • Good health, as determined by no findings from medical history.
  • History of a minimum of 1 bowel movement per day.
  • Able to comprehend and are willing to sign the Form (ICF) and abide by the study restrictions.

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
  • Confirmed systolic blood pressure >140 or \<90 mmHg, diastolic blood pressure >90 or \<50 mmHg, or pulse rate >100 or \<40 beats per minute.
  • Alcohol consumption of >21 units per week for males.
  • Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
  • Ingestion of caffeine-containing foods or beverages within 48 hours of check-in or intend to ingest caffeine-containing foods or beverages until end of study.
  • Use of tobacco- or nicotine-containing products within 3 months prior to check-in, or positive cotinine at screening or check-in.
  • Ingestion of Seville orange- or grapefruit-containing foods or beverages within 7 days prior to check-in.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Single Arm: [14C]-BGB-16673

    Participants will receive a single dose of \[14C\]-BGB-16673

    Drug: [14C]-BGB-16673

Interventions

06

What researchers measure

Primary outcomes

  1. Total Radioactivity Recovery (fet1-t2) in Urine and Feces

    Time frame: Approximately 35 Days

  2. Area Under the Plasma Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-∞) of BGB-16673

    Time frame: Approximately 35 Days

  3. Area Under the Plasma Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-∞) for Total Radioactivity in Plasma and Whole Blood

    Time frame: Approximately 35 Days

  4. Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) of BGB-16673

    Time frame: Approximately 35 Days

  5. Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) for Total Radioactivity in Plasma and Whole Blood

    Time frame: Approximately 35 Days

  6. Maximum Observed Plasma Concentration (Cmax) of BGB-16673

    Time frame: Approximately 35 Days

  7. Maximum Observed Plasma Concentration (Cmax) for Total Radioactivity in Plasma and Whole Blood

    Time frame: Approximately 35 Days

  8. Time of the Maximum Observed Plasma Concentration (Tmax) of BGB-16673

    Time frame: Approximately 35 Days

  9. Time of the Maximum Observed Plasma Concentration (Tmax) for Total Radioactivity in Plasma and Whole Blood

    Time frame: Approximately 35 Days

  10. Apparent Terminal Elimination Half-life (t1/2) of BGB-16673

    Time frame: Approximately 35 Days

  11. Apparent Terminal Elimination Half-life (t1/2) for Total Radioactivity in Plasma and Whole Blood

    Time frame: Approximately 35 Days

  12. Urinary recovery of BGB-16673 (fet1-t2)

    Time frame: Approximately 35 Days

  13. Quantitative metabolic profiles of BGB-16673 in plasma and excreta

    Time frame: Approximately 35 Days

  14. Identification of BGB-16673 major metabolites in plasma and excreta

    Time frame: Approximately 35 Days

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs)

    Time frame: Approximately 35 days

  2. Number of Participants with Clinically Significant Laboratory Values

    Time frame: Approximately 9 weeks

  3. Number of Participants with Clinically Significant Electrocardiogram (ECG) Results

    Time frame: Approximately 9 weeks

  4. Number of Participants with Clinically Significant Vital Sign Measurements

    Time frame: Approximately 9 weeks

07

Study locations

1 site
  • Fortrea Clinical Research Unit Inc
    Madison, Wisconsin 53704-2526, United States
08

References and documents

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Mar 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 15, 2025
StartActual
Jan 24, 2025
Primary completionActual
Mar 27, 2025
CompletionActual
Mar 27, 2025
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06776679
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Jan 24, 2025
Primary completion
Mar 27, 2025
Completion
Mar 27, 2025
Last update
May 1, 2025

Study contacts

Study Director Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacabrutideg

Start the discussion